Objective
Based on an international team derived from the COST action BM1003 (www.cost-bm1003.info 2011-2014) and thus relying on consolidated group interactions and synergies and on a unique combination of chemistry, biology, biophysics, biochemistry and pharmacology expertise, the TOLLerant project aims to gain information on molecular aspects of TLR4 activation and signaling by using synthetic and natural compounds and nanoparticles that interact selectively with some components (mainly MD-2 and CD14) of the TRL4 recognition system.
TLR4 is an emerging molecular target related to an impressively broad spectrum of modern day disorders still lacking specific pharmacological treatment. These include autoimmune disorders, chronic inflammations, allergies, asthma, infectious and CNS diseases and cancer.
The short-term scientific objective is to develop novel, non-toxic, synthetic and natural TLR4 modulators (agonists or antagonists) and to assess their therapeutic potential on animal models of TLR4-related acute and chronic pathologies that still lack efficient pharmacological treatment. The long-term scientific objective is to develop a new generation of innovative, TLR4-based therapeutics, to be used as vaccine adjuvants, anti-sepsis agents, and anti-inflammatory agents to treat chronic inflammations (allergy, asthma). The training programme will provide Early Stage Researchers (ESR) with broad competences, experience and skills in the cutting-edge, inter-disciplinary research in the field of chemical biology related to the molecular mechanisms of innate immunity and inflammation. During the training, the young researchers will be supported by senior scientists to cultivate their scientific, entrepreneurial and inter-cultural mindset. The non-academic sector will be committed to provide ESRs with entrepreneurship and company management skills, in order to enhance their employability by the private sector or even to motivate them to create own start-up companies.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences clinical medicine pneumology asthma
- medical and health sciences basic medicine medicinal chemistry
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine allergology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-ITN-ETN - European Training Networks
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-ITN-2014
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
20126 Milano
Italy
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.